JP2024543204A - インターロイキン－２３受容体のペプチド阻害剤 - Google Patents

インターロイキン－２３受容体のペプチド阻害剤 Download PDF

Info

Publication number
JP2024543204A
JP2024543204A JP2024532708A JP2024532708A JP2024543204A JP 2024543204 A JP2024543204 A JP 2024543204A JP 2024532708 A JP2024532708 A JP 2024532708A JP 2024532708 A JP2024532708 A JP 2024532708A JP 2024543204 A JP2024543204 A JP 2024543204A
Authority
JP
Japan
Prior art keywords
bridge
arg
ala
aminomethyl
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543204A5 (enExample
Inventor
ヘンリック フィッシャー マンチ
ニールス ビェアア ホルム
ラスムス レス
ビャーネ ドゥーウ ラースン
ジェスパー モゾルフ マティーアスン
オクタブ カルダラル
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2024543204A publication Critical patent/JP2024543204A/ja
Publication of JP2024543204A5 publication Critical patent/JP2024543204A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024532708A 2021-12-01 2022-12-01 インターロイキン－２３受容体のペプチド阻害剤 Pending JP2024543204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21211815.2 2021-12-01
EP21211815 2021-12-01
PCT/EP2022/084077 WO2023099669A1 (en) 2021-12-01 2022-12-01 Peptide inhibitors of interleukin-23 receptor

Publications (2)

Publication Number Publication Date
JP2024543204A true JP2024543204A (ja) 2024-11-19
JP2024543204A5 JP2024543204A5 (enExample) 2025-12-05

Family

ID=78821013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532708A Pending JP2024543204A (ja) 2021-12-01 2022-12-01 インターロイキン－２３受容体のペプチド阻害剤

Country Status (12)

Country Link
US (1) US20250154198A1 (enExample)
EP (1) EP4440592A1 (enExample)
JP (1) JP2024543204A (enExample)
KR (1) KR20240111800A (enExample)
CN (1) CN118354781A (enExample)
AU (1) AU2022402440A1 (enExample)
CA (1) CA3240982A1 (enExample)
CL (1) CL2024001598A1 (enExample)
IL (1) IL313185A (enExample)
MX (1) MX2024006556A (enExample)
TW (1) TW202332682A (enExample)
WO (1) WO2023099669A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) * 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
MX384213B (es) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
CL2024001598A1 (es) 2024-11-15
IL313185A (en) 2024-07-01
MX2024006556A (es) 2024-06-12
TW202332682A (zh) 2023-08-16
WO2023099669A1 (en) 2023-06-08
CA3240982A1 (en) 2023-06-08
US20250154198A1 (en) 2025-05-15
AU2022402440A1 (en) 2024-05-30
CN118354781A (zh) 2024-07-16
KR20240111800A (ko) 2024-07-17
EP4440592A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2024543204A (ja) インターロイキン－２３受容体のペプチド阻害剤
DK2694095T3 (en) COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
RS66991B1 (sr) Peptidni inhibitori interleukin-23 receptora i njihova primena u lečenju inflamatornih bolesti
US20240352073A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
TW202116793A (zh) 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
CN114341161A (zh) 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
CN120019064A (zh) Il-23的环肽抑制剂
CA2793683A1 (en) Peptidomimetics for modulating interleukin-1 receptor
EP4471049A1 (en) Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) Peptide inhibitors of interleukin-23 receptor
WO2014119753A4 (ja) マイオスタチン阻害ペプチド
KR20250028290A (ko) 선택적 il-23 수용체 길항제로서의 새로운 펩티드
TW202607011A (zh) 介白素－２３受體之胜肽抑制劑
WO2026013260A1 (en) Peptide inhibitors of interleukin-23 receptor
KR20250163313A (ko) Tnf-알파 결합제 및 이를 사용하는 방법
TW202602903A (zh) 肽、肽複合物、醫藥組成物、細胞培養用組成物以及用於醫療用、診斷用或研究用的組成物
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251127